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(57) ABSTRACT 
In various embodiments, the present disclosure describes 
fullerene derivatives that are capable of photocatalytically 
generating reactive oxygen species in the presence of ultra-
violet and/or visible light. In some embodiments, the 
fullerene derivatives are aminofullerenes containing a plural-
ity of amine-terminated moieties covalently bonded to the 
fullerene cage. The fullerene derivatives may optionally be 
covalently bonded to a substrate surface for use in photocata-
lytic disinfection systems for removing various contaminants 
including, for example, bacteria, viruses, protozoa and 
chemical pollutants. Methods using the present fullerene and 
aminofullerene derivatives in various purification processes 
are also described herein. 
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1 
FULLERENE COMPOSITIONS AND 
METHODS FOR PHOTOCHEMICAL 
PURIFICATION 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
for photochemical removal of contaminants from various 
sources, provided that successful generation ofreactive oxy-
gen species can be achieved in such functionalized C60 
derivatives. Compositions containing such C60 derivatives 
would have particular utility in water and air purification to 
remove a number of biological and chemical contaminants, 
while using only atmospheric oxygen and light in the purifi-
This application claims priority to U.S. Provisional Patent cation process. 
Applications 61/220,093, filed Jun. 24, 2009, and 61/256, 
043, filed Oct. 29, 2009, each of which is incorporated by 10 
reference herein in its entirety. 
SUMMARY 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
In some embodiments, fullerene derivatives operable for 
photocatalytically generating singlet oxygen in the presence 
15 
of a visible light source are described herein. 
In some embodiments, photocatalytic disinfection systems 
containing a substrate surface and at least one fullerene 
derivative covalently bonded to the substrate surface are 
described herein. The at least one fullerene derivative is oper-
This invention was made with Govermnent support under 
grant numbers CBET-0829158 and EEC-0647452 awarded 
by the National Science Foundation. The Govermnent has 
certain rights in the invention. 
BACKGROUND 
Buckminsterfullerene (C60) has been shown to have a num-
ber of useful photophysical properties that have led to pro-
posed uses including, for example, photoconductive, photo-
chemical and photovoltaic devices, as well as photodynamic 
therapy. Upon irradiation, the ground state ofC60 becomes an 
excited singlet state (1C60), which subsequently converts to 
20 able for forming at least one reactive oxygen species in the 
presence of a light source. In some embodiments, the photo-
catalytic disinfection systems further contain an ultraviolet or 
visible light source. 
In other various embodiments, methods for using the 
an excited triplet state (3C60) in unit quantum yield through 
intersystem crossing. In the presence of dissolved oxygen, 
energy transfer from the c60 triplet state to the dissolved 
oxygen results inefficient production of singlet oxygen (102). 
25 present fullerene derivatives in photochemical purification 
processes are described herein. In some embodiments the 
methods include providing a composition containing at least 
one fullerene derivative that is operable for forming at least 
one reactive oxygen species in the presence of a light source, 
In addition the C60 triplet state can be reduced to a C60 radical 
anion (C60 _-) in the presence of electron donors such as, for 
example, amines and alcohols. The C60 radical anion, in tum, 
can reduce dissolved oxygen to form a superoxide radical 
anion (02 _-). FIGS. lA and lB present schematics showing 
various processes through which C60 can produce reactive 
oxygen species (singlet oxygen and superoxide radical anion) 
under irradiation conditions. 
30 exposing the composition to a material containing at least one 
contaminant, and irradiating the composition with a light 
source to generate at least one reactive oxygen species. The at 
least one reactive oxygen species reacts with the at least one 
contaminant. 
35 In some embodiments, the methods include providing a 
composition containing at least one aminofullerene 
covalently bonded to a substrate surface, exposing the com-
position to a material containing at least one contaminant, and 
irradiating the composition with a light source to generate at 
Efforts to harness the photophysical properties of C60 for 
environmental and biomedical applications have been ham-
pered by its low aqueous solubility. Although aqueous solu-
bility can be addressed by functionalization, the photophysi-
40 least one reactive oxygen species that reacts with the at least 
one contaminant. The at least one aminofullerene is operable 
for forming at least one reactive oxygen species in the pres-
ence of a light source. The at least one aminofullerene has a 
structure of 
cal activity of functionalized C60 is substantially reduced or 45 
eliminated in many instances due to aggregation in solution. 
Aggregation in solution generally results in contact between 
the fullerene cages of adjacent C60 moieties, resulting in 
photoquenching of the triplet state. 
Various functionalized C60 derivatives have been proposed 50 
for biomedical therapeutic applications including, for 
example, tumor growth inhibition, DNA cleavage, and anti-
microbial activity against HIV-1. For environmental applica-
tions, it has been shown that under UV irradiation, fullerols 
(e.g., multiple-hydroxy lated C60) can be used to form reactive 55 
oxygen species, which can subsequently inactivate MS-2 
bacteriophage and other pathogens, as well as destroy chemi-
A represents a C2 m fullerene cage, where mis greater than or 
equal to 30. X 1 andX2 are independently 0 or NR3 , where R3 
is H, alkyl, cycloalkyl, aryl, heteroaryl, or aralkyl. R1 and R2 
contain at least one terminal amino group and are indepen-
dently alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, 
heteroaryl, or aralkyl groups. Variable n is an integer ranging 
from 1 to an upper limit equal to half the number of hexagons 
cal pollutants. However, it has not been heretofore demon-
strated that microbial, viral orotherpathogeninactivationcan 
occur in the presence of visible light, which would enable the 60 
use of the sun as a natural light source to affect photochemical 
purification and environmental remediation. Furthermore, 
catalytic reuse of fullerene derivatives bound to a substrate 
surface has not yet been demonstrated in environmental 
applications. 65 in the C2 m fullerene cage. 
In view of the foregoing, C60 derivatives and substrate-
bound variants thereof would demonstrate substantial utility 
In some embodiments, methods of the present disclosure 
include providing a composition containing at least one ami-
US 8,679,442 B2 
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nofullerene covalently bonded to a substrate surface, expos-
ing the composition to a material containing at least one 
contaminant, and irradiating the composition with a visible 
light source to generate at least one reactive oxygen species. 
The at least one aminofullerene contains C60 and a plurality of 
amine-terminated moieties covalently bonded to the C60 . The 
at least one aminofullerene is operable for forming at least 
one reactive oxygen species in the presence of a visible light 
source. 
The foregoing has outlined rather broadly the features of 
the present disclosure in order that the detailed description 
that follows may be better understood. Additional features 
and advantages of the disclosure will be described hereinaf-
ter, which form the subject of the claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
4 
FIG. 12 shows illustrative plots of MS-2 bacteriophage 
inactivation as a function of irradiation time by hexakis-
substituted C60 fullerene derivative 4 in comparison to Ti02 ; 
FIG. 13 shows illustrative UV-VIS reflectance spectra of 
various concentrations of hexakis-substituted C60 fullerene 
derivative 4 covalently bound to a functionalized silica gel 
support; 
FIG. 14 shows illustrative plots of fractional FFA remain-
ing as a function ofirradiation time for various concentrations 
10 of silica-bound hexakis-substituted c60 fullerene derivative 4 
in the presence and absence of a UV cutoff filter; 
15 
FIG. 15 shows illustrative plots of fractional FFA remain-
ing as a function of irradiation time for Ti02 in the presence 
and absence of a UV cutoff filter; and 
For a more complete understanding of the present disclo-
sure, and the advantages thereof, reference is now made to the 20 
following descriptions to be taken in conjunction with the 
accompanying drawings describing specific embodiments of 
the disclosure, wherein: 
FIG.16 shows illustrative plots of fractional concentration 
as a function of irradiation time for ranitidine, cimetidine, 
propanolol and sulfisoxazole in the presence of silica-bound 
hexakis-substituted c60 fullerene derivative 4 at a light inten-
sity of 55 µw/cm2 (350 650 nm). 
DETAILED DESCRIPTION 
In the following description, certain details are set forth 
such as specific quantities, sizes, etc. so as to provide a thor-
ough understanding of the present embodiments disclosed 
herein. However, it will be evident to those of ordinary skill in 
FIGS. lA and lB present schematics showing various pro-
cesses through which C60 can produce reactive oxygen spe- 25 
cies (singlet oxygen and superoxide radical anion) under 
irradiation conditions; the art that the present disclosure may be practiced without 
such specific details. In many cases, details concerning such 
considerations and the like have been omitted inasmuch as 
FIGS. 2A-2D show illustrative synthetic routes used for 
synthesizing hexakis-substituted c60 fullerene derivatives 
1-4; FIG. 2E shows an illustrative synthetic route used for 30 
appending hexakis-substituted c60 fullerene derivative 4 to a 
silica surface; 
such details are not necessary to obtain a complete under-
standing of the present disclosure and are within the skills of 
persons of ordinary skill in the relevant art. 
Referring to the drawings in general, it will be understood 
that the illustrations are for the purpose of describing particu-
lar embodiments of the disclosure and are not intended to be 
limiting thereto. Drawings are not necessarily to scale. 
FIG. 3 shows illustrative plots of fractional furfuryl alcohol 
remaining in the presence of various hexakis-substituted C60 
fullerene derivatives and fullerol as a function of irradiation 35 
time; 
FIG. 4 shows illustrative electron paramagnetic resonance 
(EPR) spectra ofhexakis-substituted C60 fullerene derivative 
4 as a function of irradiation time in the presence of 2,2,6,6-
tetramethyl-4-piperidinol as a spin-trapping reagent; 
FIG. 5 shows illustrative plots of triplet state decay kinetics 
in various hexakis-substituted c60 fullerene derivatives in 
comparison to fullerol; 
FIGS. 6A and 6B show illustrative particle size histograms 
for various hexakis-substituted c60 fullerene derivatives 
deposited from a water solution and a 10 mM phosphate 
buffer solution; 
FIG. 7 shows illustrative plots of E. coli inactivation as a 
function of irradiation time by various hexakis-substituted 
C60 fullerene derivatives in comparison to fullerol and Ti02; 
FIG. 8 shows illustrative plots of E. coli inactivation as a 
function of irradiation time by hexakis-substituted c60 
fullerene derivative 4 in UV light both in the presence and 
absence ofL-histidine scavenger and in the dark; 
FIG. 9 shows illustrative plots ofMS-2 bacteriophage inac-
tivation as a function of irradiation time by various hexakis-
substituted c60 fullerene derivatives in comparison to fulle-
rol; 
FIG. 10 shows illustrative plots of MS-2 bacteriophage 
inactivation as a function of irradiation time by various con-
centrations ofhexakis-substituted c60 fullerene derivative 4; 
FIG. 11 shows illustrative plots of MS-2 bacteriophage 
inactivation as a function of irradiation time by hexakis-
substituted C60 fullerene derivative 4 at 10 µM in UV light 
both in the presence and absence ofL-histidine scavenger and 
in the dark; 
While most of the terms used herein will be recognizable to 
those of ordinary skill in the art, it should be understood, 
however, that when not explicitly defined, terms should be 
40 interpreted as adopting a meaning presently accepted by 
those of ordinary skill in the art. In cases where the construc-
tion of a term would render it meaningless or essentially 
meaningless, the definition should be taken from Webster's 
Dictionary, 3rd Edition, 2009. Definitions and/or interpreta-
45 tions should not be incorporated from other patent applica-
tions, patents, or publications, related or not, unless specifi-
cally stated in this specification or if the incorporation is 
necessary for maintaining validity. 
The following definitions are set forth to aid in understand-
50 ing of the various embodiments of the present disclosure. 
Terms in addition to those below are defined, as required, 
throughout the Detailed Description. 
"Alkyl and cycloalkyl," as used herein, respectively refer to 
carbon chains and rings having all saturated carbon-carbon 
55 bonds. Alkyl groups of the present disclosure contain from 1 
to about 20 carbon atoms and may be linear or branched. 
Cycloalkyl groups of the present disclosure may be monocy-
clic or multi-cyclic and contain from 3 to about 20 carbon 
atoms. Alkyl and cycloalkyl groups may further be substi-
60 tuted with heteroatom functionality (e.g., halogens, alcohols, 
thiols, ethers, thioethers, aldehydes, ketones, amines, car-
boxylic acids, esters, amides, nitriles, and like functionality). 
Heteroatom functionality (e.g., N, 0 or S from, for example, 
alcohols, thiols, ethers, thioethers or amines) may replace a 
65 carbon atom in the chain of alkyl groups. In suchheteroatom-
substituted alkyl groups, all of the carbon-carbon or carbon-
heteroatom bonds remain saturated. 
US 8,679,442 B2 
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"Heterocyclyl," as used herein, refers to a cycloalkyl group 
having at least one ring carbon atom replaced with a heteroa-
tom (e.g., N, 0 or S from, for example, alcohols, thiols, ethers, 
thioethers or amines). 
"Alkenyl and alkynyl," as used herein, refer to linear or 
branched carbon chains having at least one carbon-carbon 
double bond ( alkenyl) or carbon-carbon triple bond ( alkynyl). 
Alkenyl and alkynyl groups of the present disclosure contain 
from 2 to about 20 carbon atoms and may be further substi-
tuted with heteroatom functionality, as noted above. 10 
"Ary!," as used herein, refers to aromatic monocylic or 
multi-cyclic rings having from 6 to about 20 carbon atoms. 
Ary! groups of the present disclosure may be further substi-
tuted with heteroatom functionality, as noted above. 15 
"Heteroary !,"as used herein, refers to monocyclic or multi-
cyclic aromatic rings containing at least 1 to about 4 heteroa-
toms (e.g., 0, N, S) and about 4 to about 20 carbon atoms. 
Heteroaryl groups of the present disclosure may be further 
substituted with heteroatom functionality, as noted above. 20 
6 
hexagons (e.g., 6-membered rings) in the C2 m fullerene cage. 
For example, in C60 there are 20 hexagons, and n ranges 
between 1 and 10. In larger fullerene cages, there are more 
hexagons, and the upper limit of n is accordingly higher. 
Depending on the chosen fullerene, one of ordinary skill in 
the art will readily be able to determine the number of hexa-
gons therein in order to establish the upper limit of variable n. 
Variable n ranges between 1 and 10 in some embodiments or 
between 1 and 6 in other embodiments. 
In some embodiments, X 1 and X2 are the same, while in 
other embodiments X 1 and X2 are different. In some embodi-
ments, R1 and R2 are the same, while in other embodiments, 
R1 and R2 are different. In still other embodiments, R1 and R2 
are the same, and X 1 and X2 are the same. 
In some embodiments, the present disclosure describes 
fullerene derivatives that are operable for photocatalytically 
generating singlet oxygen in the presence of a visible light 
source. In some embodiments, the fullerene derivatives are 
C60 (buckminsterfullerene) derivatives [e.g., (C60-Ih)[5,6] 
fullerene derivatives]. However, in other embodiments, the 
fullerene derivatives may contain higher fullerenes such as, 
for example, C70 , C76, C78 , C82 and C84. In some embodi-
"Aralkyl," as used herein, refers to an alkyl group having at 
least one of its hydrogen atoms replaced with an aromatic 
group. Aralkyl groups of the present disclosure may be fur-
ther substituted with heteroatom functionality, as noted 
above. 
In various embodiments, the present disclosure describes 
fullerene derivatives that are operable for generating reactive 
oxygen species such as, for example, singlet oxygen or super-
oxide radical anions in the presence of light sources such as, 
25 ments, the fullerene derivatives contain fullerene cages hav-
ing a carbon count between sixty carbons (e.g., C60) and 120 
carbons (e.g., C120). In general, the fullerene derivatives con-
tain fullerene cages having a carbon count of C2m, where mis 
an integer greater than or equal to 30. In various embodi-
for example, ultraviolet and/or visible light sources. In vari-
ous embodiments, the fullerene derivatives are aminof-
ullerene derivatives containing a terminal amino group that 
may be covalently bonded to a substrate surface through an 
amide bond, for example. When covalently bonded to a sub-
strate surface, the fullerene or aminofullerene derivatives are 35 
still operable for generating reactive oxygen species. The 
reactive oxygen species may be subsequently used in various 
purification processes for media including, for example, air 
and water to remove contaminants therefrom (e.g., bacterial 
and viral pathogens and chemical impurities). Photocatalytic 40 
disinfection systems containing the present fullerene deriva-
tives and methods for use thereof are also described herein. 
In general, aminofullerenes of the present disclosure have 
the following structure: 
0 
0 
30 ments, the fullerene cages of the present fullerene derivatives 
are not hydroxylated. 
Fullerene derivatives of the present disclosure may contain 
any number of substituents up to the maximum allowed by the 
chosen fullerene cage (e.g., an upper limit equal to half the 
number of hexagons in the fullerene cage). However, in many 
embodiments of the present disclosure, the fullerene deriva-
tives contain fewer substituents than the maximum allowed 
amount. In some embodiments, the fullerene derivatives are 
hexakis-substituted fullerene derivatives, meaning that they 
contain six substituents covalently bonded to the fullerene 
cage. In embodiments in which the fullerene is C60, hexakis-
substituted c60 fullerene derivatives generally possess a 
highly symmetrical structure and are easily isolated and char-
45 acterized spectroscopically. In some embodiments, illustra-
tive hexakis-substituted c60 fullerene derivatives may include 
the following, for example: 
50 
55 
where A represents a C2 m fullerene cage, where m is greater 
than or equal to 30, and X 1 and X2 are independently 0 or 
NR3 , where R3 is H, alkyl, cycloalkyl, aryl, heteroaryl, or 60 
aralkyl. R1 and R2 contain at least one terminal amino group 
and are independently alkyl, alkenyl, alkynyl, cycloalkyl, 
heterocyclyl, aryl, heteroaryl, or aralkyl groups. In various 
embodiments, the at least one terminal amino group ofR1 and 
R2 may by primary, secondary or tertiary. 65 
In some embodiments, variable n is an integer ranging 
between 1 and an upper limit equal to half the number of 
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-continued subsituted c60 derivatives 1-4 also demonstrate the capacity 
2 for generating singlet oxygen during irradiation. In general, 
any substituted fullerene derivative having a number of sub-
stituents between 1 and an upper limit equal to half the num-
ber of hexagons in the fullerene cage may be utilized in the 
various embodiments described herein. 
~ OH 
HN 
0 
0 
HN ('OH 
OH 
and 
In some embodiments, the fullerene derivatives of the 
present disclosure are aminofullerenes containing C60 and a 
plurality of amine-terminated moieties covalently bonded to 
10 the C60 . In some embodiments, the aminofullerenes are C60 
derivatives containing between 1 and 6 substitutents. In some 
embodiments, the aminofullerene is hexakis-substituted c60 
derivative 4. However, as previously set forth hereinabove, a 
15 wide variety of aminofullerenes lie within the spirit and scope 
of the present disclosure. 
In some embodiments, the fullerene derivatives may fur-
ther be covalently bonded to a substrate surface such as, for 
example, a polymer, metal or silica gel surface. In some 
20 embodiments, at least one terminal amino group of an ami-
nofullerene may be covalently bonded to a substrate surface. 
For example, in some embodiments, terminal amino group(s) 
of aminofullerenes may be covalently bonded to a substrate 
surface through amide bond(s) between the aminofullerene 
25 and the substrate surface. One of ordinary skill in the art will 
appreciate that there are many ways in which fullerene deriva-
tives might become covalently bonded to a substrate surface, 
and the illustrative examples presented herein should not be 
construed as limiting. 
4 30 In some embodiments, photocatalytic disinfection systems 
Various salts and combinations of the aforesaid fullerene 
derivatives also lie within the spirit and scope of the present 
disclosure. For example, in various embodiments, one or 
more amines of hexakis-substituted C60 derivative 4 may 
exist in a salt form (e.g., chloride or trifluoroacetate ). 
The embodiments of the present disclosure are by no 
means limited to hexakis-substituted fullerene derivatives. In 
some embodiments, the fullerene derivatives are mono-sub-
stituted fullerene derivatives (e.g., mono-substituted C60 
derivatives). In some embodiments, the fullerene derivatives 
are di-substituted fullerene derivatives (e.g., di-substituted 
C60 derivatives). In some embodiments, the fullerene deriva-
tives are tri-substituted fullerene derivatives (e.g., tri-substi-
tuted C60 derivatives). In some embodiments, the fullerene 
derivatives are tetrakis-substituted fullerene derivatives (e.g., 
tetrakis-substituted C60 derivatives). In some embodiments, 
the fullerene derivatives are pentakis-substituted fullerene 
derivatives (e.g., pentakis-substituted C60 derivatives). For 
example, bis- and tetrakis-substituted variants of hexakis-
containing fullerene derivatives are described herein. In vari-
ous embodiments, the photocatalytic disinfection systems 
include a substrate surface and at least one fullerene deriva-
tive covalently bonded to the substrate surface. The at least 
35 one fullerene derivative is operable for forming at least one 
reactive oxygen species in the presence of a light source. In 
some embodiments, the photocatalytic disinfection systems 
further include a visible light source. 
In some embodiments, the photocatalytic disinfection sys-
40 terns further include a visible light source. The visible light 
source emits wavelengths between about 400 nm and about 
700 nm in some embodiments or between about 400 nm and 
about 550 nm in other embodiments. Illustrative visible light 
sources include, for example, tungsten lamps and other incan-
45 descent light sources, mercury vapor lamps, light-emitting 
diodes, arc discharge lamps and lasers. In some embodi-
ments, the visible light source is predominantly a line source 
such as, for example, a laser. In other embodiments, the 
visible light source is a broad spectrum emitter such as, for 
50 example, an incandescent light source. In some embodi-
ments, the visible light source is the sun. 
In some embodiments, the photocatalytic disinfection sys-
tems further include an ultraviolet light source. In some 
embodiments, the ultraviolet light source emits wavelengths 
55 between about 10 nm and about 400 nm. In general, ultravio-
let wavelengths below about 200 nm are referred to as the 
vacuum ultraviolet, since these wavelengths are strongly 
absorbed by air. In some embodiments of the present disclo-
sure, the ultraviolet light source emits wavelengths between 
60 about 200 nm and about 400 nm. Illustrative ultraviolet light 
sources include, for example, ultraviolet fluorescent lamps 
[e.g., black light blue (BLB) lamps], low pressure mercury 
vapor lamps, light emitting diodes, lasers and arc discharge 
lamps. In some embodiments, the ultraviolet light source is 
65 predominantly a line source such as, for example, a laser. In 
other embodiments, the ultraviolet light source is a broad 
spectrum emitter. 
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In some embodiments, the photocatalytic disinfection sys-
tems further include a mixed light source including both 
ultraviolet and visible light. In some embodiments, the mixed 
light source includes two or more separate light sources such 
as, for example, two or more lamps or lasers. In other embodi-
ments, the mixed light source is a single light source emitting 
light in both the ultraviolet and visible regions of the electro-
magnetic spectrum. In some embodiments, the mixed light 
source is the sun. 
10 
1 and about 30 substituents on the fullerene cages. In various 
embodiments, the substituents may contain terminal func-
tional groups operable for forming covalent bonds with suit-
able functional groups on a substrate surface. For example, 
alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or aralkyl 
groups terminated with carboxylic acid, amine, hydroxyl or 
like functional groups may readily react with complementary 
functional groups on a substrate surface. In some or other 
embodiments, the substitutents on the fullerene derivatives 
Reactive oxygen species include, for example, singlet oxy-
gen, superoxide radical anions, hydroxyl radicals, and hydro-
gen peroxide. In general, the fullerene derivatives of the 
present disclosure are operable for generating singlet oxygen 
upon exposure to a light source, as will be shown hereinafter 
10 
may also contain functional groups having an affinity toward 
a particular microorganism or virus, which may allow for 
selective pathogenic targeting under photocatalytic disinfec-
tion conditions. 
in the experimental examples. In some embodiments, the 15 
fullerene derivatives are operable for photocatalytically gen-
erating singlet oxygen in the presence of ultraviolet light. In 
other embodiments, the fullerene derivatives are operable for 
photocatalytically generating singlet oxygen in the presence 
of visible light. Visible light generation of reactive oxygen 20 
species (e.g., singlet oxygen) represents a particular advan-
tage of the present fullerene derivatives and photocatalytic 
disinfection systems, as the solar spectrum may be used in an 
embodiment to generate reactive oxygen species. Use of the 
solar spectrum to generate reactive oxygen species advanta- 25 
geously allows the present fullerene derivatives and photo-
catalytic disinfection systems to be used in the absence of an 
external power supply for a light source, which is not possible 
when conventional photocatalysts are used. Production of 
reactive oxygen species in the presence of visible light par- 30 
ticularly distinguishes the present fullerene derivatives over 
conventional photocatalysts such as, for example, Ti02 that 
are commonly used in photocatalytic disinfection systems. 
In various embodiments of the photocatalytic disinfection 
systems, the at least one fullerene derivative is a C60 deriva- 35 
tive. However, as discussed hereinabove, a wide variety of 
fullerene derivatives may be utilized in the present photocata-
lytic disinfection systems. In some embodiments, the at least 
one fullerene derivative may contain a higher fullerene such 
as, for example, a derivative of C70, C76 , C78 , C82 or C84. In 40 
some embodiments, the at least one fullerene derivative may 
have a fullerene cage having a carbon count between sixty 
carbons (e.g., C60) and 120 carbons (e.g., C120, or, more 
generally, the fullerene cage of the at least one fullerene 
derivative may have C2 m carbons, where m is greater than or 45 
equal to 30. In various embodiments of the present photocata-
lytic disinfection systems, the at least one fullerene derivative 
contain fullerene cages that are not hydroxylated. 
In some embodiments of the photocatalytic disinfection 
systems, the at least one fullerene derivative is a single 50 
fullerene derivative. In some embodiments, the at least one 
fullerene derivative is a mono-substituted fullerene deriva-
tive. In some embodiments, the at least one fullerene deriva-
tive is a di-substituted fullerene derivative. In some embodi-
ments, the at least one fullerene derivative is a tri-substituted 55 
fullerene derivative. In some embodiments, the at least one 
fullerene derivative is a tetrakis-substituted fullerene deriva-
tive. In some embodiments, the at least one fullerene deriva-
tive is a pentakis-substituted fullerene derivative. In some 
embodiments, the at least one fullerene derivative is a 60 
hexakis-substituted fullerene derivative. In other embodi-
ments, the at least one fullerene derivative of the present 
photocatalytic disinfection systems is a mixture of fullerene 
derivatives (e.g., a mixture of at least two different substituted 
fullerene derivatives, each containing different numbers of 65 
substitutents). In some embodiments, such mixtures of 
fullerene derivatives contain fullerenes each having between 
In some embodiments of the photocatalytic disinfection 
systems, the at least one fullerene derivative is a hexakis-
substituted C60 derivative such as, for example, 
2 
0 
(/" 
HN 
0 
and 
0 
HN 
rOH 
OH 
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4 
including various salts (e.g., chloride or trifluoroacetate) and 
combinations thereof. In some embodiments, the at least one 
fullerene derivative of the photocatalytic disinfection systems 
is at least one aminofullerene containing C60 and a plurality of 
amine-terminated moieties covalently bonded to the C60 (e.g., 
hexakis-substituted C60 derivative 4 ). In general, the aminof-
ullerenes of the present photocatalytic disinfection systems 
may have the following generic structure: 
0 
0 
where the variables are defined as previously set forth here-
inabove. 
12 
embodiments, the fullerene derivatives are covalently bonded 
to multiple substrate surfaces. For example, when the sub-
strate surface is a continuous surface (e.g., a sheet), the 
fullerene derivative may be bonded to the substrate surface by 
one covalent bond or more than one covalent bond (e.g., 
amide bonds for aminofullerene derivatives). However, when 
the substrate surface is in a particulate form such as, for 
example, silica particles, the fullerene derivative maybe 
bonded to multiple particles such that the fullerene derivative 
10 bridges between individual particles. Alternately, however, 
the fullerene derivative may be covalently bound to only a 
single substrate surface, even when the substrate surface is in 
a particulate form. Covalent bonding of the present fullerene 
derivatives to substrate surfaces is advantageous in that it 
15 produces a more stable interface than can be obtained with 
photocatalysts that are not capable of being functionalized. 
Stated another way, covalent bonding allows a more robust 
photocatalyst-substrate surface interaction than is possible 
using conventional photocatalysts, thereby providing longer 
20 field lifetimes in the present photocatalytic disinfection sys-
tems. 
When covalently bonded to a substrate surface, the at least 
one fullerene derivative may generate either more or less 
reactive oxygen species than the free fullerene derivative not 
25 covalently bonded to a substrate surface. In some embodi-
ments, the at least one fullerene derivative generates more of 
the at least one reactive oxygen species when covalently 
bonded to the substrate surface than when the at least one 
fullerene derivative is not covalently bonded to the substrate 
30 surface. The ability to immobilize the present fullerene 
derivatives on a substrate surface while still maintaining the 
potential to generate significant quantities of reactive oxygen 
species is particularly advantageous for catalytic reuse in field 
applications such as, for example, environmental remedia-
35 tion. A concern with immobilization offullerene derivatives 
on a substrate surface is that reduced photocatalytic activity 
and antimicrobial activity might result due to decreased sur-
face area and possible photoquenching resulting from close 
contact between fullerene cages. Surprisingly, the fullerene 
40 derivatives of the present disclosure generally have an 
increased rate of reactive oxygen species generation when 
covalently bound to a substrate surface, leading to improved 
photocatalytic disinfection with the present systems. 
Although not required, the fullerene derivatives may option-In some embodiments, the substrate surface of the present 
photocatalytic disinfection systems may be, for example, a 
polymer, a metal or a silica surface. In some embodiments of 
the photocatalytic disinfection systems, the at least one 
fullerene derivative is an aminofullerene derivative, and the 
substrate surface is carboxylate-functionalized silica. In such 
embodiments, the present aminofullerene derivatives may be 50 
covalently bonded to the substrate surface via at least one 
amide bond originating on the silica surface. In some embodi-
ments, each aminofullerene derivative is covalently bonded to 
the carboxylate-functionalized silica by one amide bond, 
leaving other amine groups of the aminofullerene unbonded. 55 
In other embodiments, each aminofullerene derivative is 
covalently bonded to the carboxylate-functionalized silica by 
more than one amide bond, leaving some or none of the other 
amine groups of the aminofullerene unbonded. One of ordi-
nary skill in the art will recognize that various means for 60 
functionalizing silica surfaces are known in the art, and a 
number of different functionalized silica surfaces may be 
suitable for appending fullerene derivatives thereto, and the 
present examples utilizing aminofullerenes and carboxylate-
functionalized silica should not be construed as limiting. 
45 ally be covalently bound to the substrate surface through a 
long chain carbon spacer in order to move adjacent fullerene 
cages away from one another and the substrate surface and to 
increase the fullerene derivative's effective surface area in 
some embodiments. Attachment of the fullerene derivatives 
to a substrate surface via a long chain carbon spacer may 
allow further improvement in the ability of the fullerene 
derivatives to generate reactive oxygen species. 
Without being bound by theory or mechanism, the 
increased rate of reactive oxygen species generation in the 
present fullerene derivatives may result from eliminating or 
substantially minimizing the aggregation of the fullerene 
derivatives, whether covalently bonded to a substrate surface 
or as the unbound free fullerene derivative. In the unbound 
state, some of the present fullerene derivatives tend to form 
large aggregates that are potentially susceptible to photo-
quenching. However, as demonstrated hereinafter, the present 
fullerene derivatives are able to generate reactive oxygen 
species even when present in an aggregated state. By 
covalently bonding the fullerene derivatives to a substrate 
65 surface, particle aggregation may be eliminated or substan-
tially minimized, thereby further increasing the production 
rate of reactive oxygen species. 
In some embodiments, the fullerene derivatives are 
covalently bonded to a single substrate surface. In other 
US 8,679,442 B2 
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In some embodiments, a further advantage of covalently 
bonding the present fullerene derivatives to a substrate sur-
face is that the substrate surface-bound fullerene derivatives 
may be efficiently sized. For example, in some embodiments, 
particle sizes of the substrate surface-bound fullerene deriva-
tives may range from about 100 nm all the way up to about 1 
mm. These particles can be conveniently sized into more 
narrow particle size distributions for use in fixed bed and 
fluidized bed reactors and filtration units, allowing continu-
ous catalytic use of the surface-bound fullerene derivatives. 10 
Size selective separation of the particles may be accom-
plished using techniques familiar to those of ordinary skill in 
the art. Alternately, the substrate surface-bound fullerene 
derivatives may be used in any of the present embodiments 
without further sizing. 15 
Reactive oxygen species produced by the present photo-
catalytic disinfection systems may mitigate a number of envi-
ronmental contaminants. For example, in some embodi-
ments, biological pathogens such as, for example, bacteria, 
viruses and protozoa may be inactivated by reactive oxygen 20 
species produced by irradiation of the present fullerene 
derivatives. In other embodiments, trace organic contami-
nants such as, for example, pharmaceutical and petrochemi-
cal contaminants may be reacted with the reactive oxygen 
species to degrade the organic contaminants completely or 25 
partially into a more easily processed form. For example, 
highly hydrophobic organic compounds may be reacted with 
reactive oxygen species to render the compounds more 
hydrophilic for removal using other chemical or physical 
separation processes. In addition to the foregoing contami- 30 
nants, organic pollutants such as, for example, endocrine 
disruptors, pesticide residues and algal toxins may be effec-
tively remediated by the present photocatalytic disinfection 
systems. 
The use of the solar spectrum as a light source in some 35 
embodiments the present photocatalytic disinfection systems 
is particularly advantageous in that it enables field deploy-
ment of the photocatalytic disinfection systems in areas 
where conventional photocatalysts is not feasible. Specifi-
cally, since the solar spectrum may be used to affect purifi- 40 
cation, the present photocatalytic disinfection systems do not 
require an external power source in some embodiments. 
Therefore, the photocatalytic disinfection systems may be 
deployed where an external power source is not readily avail-
able or economically feasible such as, for example, rural areas 45 
and developing countries. 
Another significant advantage of the present photocatalytic 
disinfection systems is that toxic or carcinogenic byproducts 
are not produced, making the photocatalytic disinfection sys-
tems suitable for purifying water meant for human consump- 50 
tion. In contrast, in conventional chlorination and ozonation 
processes for purifying water, byproducts having known 
health effects may be produced (e.g., trihalomethanes and 
bromate). 
In other various embodiments, methods for using the 55 
present fullerene derivatives in photochemical purification 
processes are also described herein. In some embodiments the 
methods include providing a composition containing at least 
one fullerene derivative that is operable for forming at least 
one reactive oxygen species in the presence of a light source, 60 
exposing the composition to a material containing at least one 
contaminant, and irradiating the composition with a light 
source to generate at least one reactive oxygen species, which 
reacts with the at least one contaminant. In some embodi-
ments of the methods, the compositions further include a 65 
substrate surface that is covalently bonded to the at least one 
fullerene derivative. 
14 
In some embodiments of the methods, the light source is a 
visible light source. In other various embodiments of the 
methods, the light source is an ultraviolet light source. In 
some embodiments, the light source is the solar spectrum. In 
some embodiments of the methods, the reactive oxygen spe-
cies is singlet oxygen. 
In some embodiments of the methods, the at least one 
fullerene derivative is a C60 derivative. In some embodiments 
of the methods, the at least one fullerene derivative is a 
hexakis-substituted C60 derivative. In some embodiments, the 
hexakis-substituted C60 derivative may be, for example, 
HN 
0 
~OH 
0 
0 
2 
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nofullerene covalently bonded to a substrate surface, expos-
ing the composition to a material containing at least one 
contaminant, and irradiating the composition with a light 
source to generate at least one reactive oxygen species that 
reacts with the at least one contaminant. The at least one 
aminofullerene is operable for forming at least one reactive 
oxygen species in the presence of a light source. In more 
general embodiments of the methods, the at least one ami-
nofullerene has the following structure: 
combinations thereof, and salts thereof (e.g., chloride or tri- 20 
fluoroacetate). 
In some embodiments of the methods, the at least one 
fullerene derivative is at least one aminofullerene containing 
C60 and a plurality of amine-terminated moieties covalently 
bonded to the c60 (e.g., hexakis-substituted c60 derivative 4). 
where the variables are defined as previously set forth here-
25 inabove. 
In some embodiments of the methods, the composition fur-
ther includes a substrate surface covalently bonded to the at 
least one aminofullerene. In more general embodiments, ami-
nofullerenes for use in the present methods have the follow-
30 ing structure: 
In some embodiments, the at least one aminofullerene is a 
mixture ofC60 aminofullerenes. In some embodiments, the at 
least one aminofullerene is a mixture of mono-substituted, 
di-substituted, tri-substituted, tetrakis-substituted, pentakis-
substituted and hexakis-substituted C60 aminofullerenes. In 
other embodiments of the methods, the at least one aminof-
0 
0 
where the variables are defined as previously set forth here-
inabove. 
In some embodiments, the present methods may be used to 
remove at least one contaminant from a liquid source such as, 
for example, water or wastewater (e.g., industrial runoff). In 
other embodiments, the present methods may be used to 
remove at least one contaminant from a gas such as, for 
example, air or inert gases. In general, the present composi-
tions and methods may be used in a purification of either a 
liquid phase or a gas phase. Gas phase purification may be 
particularly efficacious, since the lifetime of singlet oxygen is 
greater in air than in water. 
In some embodiments of the present methods, the at least 
one contaminant is a bacterium (e.g., E. coli) or a virus (e.g., 
MS-2 bacteriophage). In other embodiments of the present 
methods, the at least one contaminant is a chemical pollutant 
such as, for example, organic small molecules. In some 
embodiments, the at least one contaminant is a pharmaceuti-
cal compound (e.g., ranitidine, cimetidine, propanolol, or 
sulfisoxazole). In some embodiments, the at least one con-
taminant is a petrochemical compound. 
In some embodiments, methods of the present disclosure 
include providing a composition containing at least one ami-
ullerene is a hexakis-substituted c60 derivative. 
In some embodiments of the methods, the light source is a 
visible light source. In other embodiments of the methods, the 
35 light source is an ultraviolet light source. In some embodi-
ments of the methods, the light source is the solar spectrum. In 
some embodiments, the at least one reactive oxygen species is 
singlet oxygen. 
40 In some embodiments, the present methods may be used to 
remove at least one contaminant from a liquid source such as, 
for example, water or wastewater. In other embodiments, the 
present methods may be used to remove at least one contami-
nant from a gas such as, for example, air or inert gases. In 
45 some embodiments of the present methods, the at least one 
contaminant is a bacterium (e.g., E.coli) or a virus (e.g., MS-2 
bacteriophage). In other embodiments of the present meth-
ods, the at least one contaminant is a chemical pollutant such 
as, for example, organic small molecules. In some embodi-
50 ments, the at least one contaminant is a pharmaceutical com-
pound (e.g., ranitidine, cimetidine, propanolol or sulfisox-
azole ). In other embodiments, the at least one contaminant is 
a petrochemical compound. 
In some embodiments, methods of the present disclosure 
55 include providing a composition containing at least one ami-
nofullerene covalently bonded to a substrate surface, expos-
ing the composition to a material containing at least one 
contaminant, and irradiating the composition with a visible 
light source to generate at least one reactive oxygen species. 
60 The at least one aminofullerene contains C60 and a plurality of 
amine-terminated moieties covalently bonded to the C60 . The 
at least one aminofullerene is operable for forming at least 
one reactive oxygen species in the presence of a visible light 
source. 
65 In some embodiments, the at least one reactive oxygen 
species is at least singlet oxygen, and the at least one con-
taminant may be, for example, a bacterium, a virus, a proto-
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zoan or combinations thereof. In such embodiments, the sin-
glet oxygen inactivates the at least one contaminant. 
In other embodiments, the at least one reactive oxygen 
species is at least singlet oxygen and the at least one contami-
nant is a chemical pollutant. In such embodiments, the singlet 
oxygen degrades the at least one contaminant. As referenced 
hereinabove, in some embodiments, the degradation may be 
complete. However, in other embodiments, the degradation 
may involve a chemical transformation that renders the at 
least one contaminant removable by other purification meth-
ods. 
EXPERIMENTAL EXAMPLES 
10 
18 
mL sample aliquots were periodically withdrawn from the 
reactor using a syringe, filtered through a 0.22 µm PTFE filter 
(Millipore), and injected into a 2 mL amber glass vial for 
further analysis. The residual FFA concentration was quanti-
fied using HPLC. FIG. 3 shows illustrative plots of fractional 
furfuryl alcohol remaining in the presence of various hexakis-
substituted C60 fullerene derivatives and fullerol as a function 
of irradiation time. Generation of singlet oxygen from com-
mercially-available fullerol is presented for comparison pur-
poses. 
Table 1 summarizes the initial degradation rate ofFFA in 
the presence ofhexakis-substituted c60 fullerene derivatives 
1-4 in comparison to commercially available fullerol and 
The following examples are provided to more fully illus-
trate some of the embodiments disclosed hereinabove. It 
should be appreciated by those of ordinary skill in the art that 
the methods disclosed in the examples that follow represent 
techniques that constitute illustrative modes for practice of 
the disclosure. Those of ordinary skill in the art should, in 
light of the present disclosure, appreciate that many changes 
can be made in the specific embodiments that are disclosed 
and still obtain a like or similar result without departing from 
the spirit and scope of the disclosure. 
15 Rose Bengal. Initial FFA degradation rates ofhexakis-substi-
tuted C60 fullerene derivatives 1-4 in the presence of L-histi-
dine and t-butanol are also presented for comparison. Excess 
L-histidine significantly inhibited the degradation rate of 
FFA, whereas the degradation rate was not significantly 
20 altered in the presence oft-butanol. Both of these results are 
indicative of singlet oxygen being the predominant reactive 
oxygen species formed under photochemical irradiation. As 
shown by the FFA degradation rate, the singlet oxygen pro-
duction of the c60 fullerene derivatives was greatest for 
Example 1 
25 hexakis-substituted c60 fullerene derivative 4 and smallest 
for hexakis-substituted C60 fullerene derivative 1. All of the 
hexakis-substituted c60 fullerene derivatives displayed 
greater singlet oxygen production rates than commercially 
available fullerol. 
Synthesis and Purification of Hexakis-Substituted C60 
Fullerene Derivatives. FIGS. 2A-2D show illustrative syn-
thetic routes used for synthesizing hexakis-substituted C60 30 
fullerene derivatives. In general, nucleophilic addition of 
malonate ester or malonate amide derivatives to C60 was 
accomplished using the Binge! reaction. Generally, C60 9 and 
a malonate ester or malonate amide derivative were dissolved 
in toluene in the presence of a base [e.g., 1,8-diazabicyclo 35 
[5.4.0]undec-7-ene (DBU) or a phosphazene base]. The 
hexakis-substituted adduct was then isolated from the reac-
tion mixture via liquid chromatography to produce hydrolyz-
able intermediates 10-13. Following hydrolysis, hexakis-sub-
stituted c60 derivatives 1-4 were isolated, purified by dialysis 40 
and dried under vacuum. 
Hexakis-substituted C60 fullerene derivative 4, an aminof-
ullerene, was further reacted with functionalized silica gel 8 
using 1-(3-dimethy laminopropy 1)-3-ethy lcarbodiimide 
hydrochloride (EDC) to form amide bonds to the silica sur- 45 
face in fullerene-functionalized silica surface 7. FIG. 2E 
shows an illustrative synthetic route used for appending 
hexakis-substituted c60 fullerene derivative 4 to a silica sur-
face. Fullerene content on the silica surface was determined 
by thermogravimetric analysis, and formation of the amide 50 
bonds was confirmed by infrared spectroscopy. 
Example 2 
TABLE 1 
Singlet Oxygen Production Rates ofHexakis-Substituted C60 Derivatives 
Initial FFA Degradation Rate 
No L-Histidine t-Butanol 
Scavenger Scavenger Scavenger 
8.18 ± 0.68 0.15 ± 0.04 6.30 ± 0.44 
2 13.28 ± 0.44 0.68 ± 0.10 11.68 ± 0.26 
11.36 ± 0.56 0.72 ±0.10 10.43 ± 0.92 
4 19.06 ± 0.60 0.28 ± 0.13 18.21 ± 0.39 
Fullerol 1.30 ± 0.19 0.25 ± 0.05 1.52±0.14 
Rose Bengal 16.34 ± 0.29 0.07 ± 0.04 16.70 ± 0.47 
FIG. 4 shows illustrative electron paramagnetic resonance 
(EPR) spectra ofhexakis-substituted C60 fullerene derivative 
4 as a function of irradiation time in the presence of 2,2,6,6-
tetramethyl-4-piperidinol as a spin-trapping reagent. The 
increased EPR signal as a function of irradiation time is 
consistent with increased single oxygen production at longer 
irradiation times. 
Example 3 
Measurement of Triplet-State Decay Kinetics in Hexakis-
Substituted C60 Fullerene Derivatives. Decay kinetics of the 
triplet states for the hexakis-substituted c60 derivatives were 
measured by laser flash photolysis using a 308 nm laser pulse 
(10-20 ml with a pulse width of 10 ns). A xenon lamp was 
Photochemically-Induced Singlet Oxygen Production 55 
from Hexakis-Substituted C60 Fullerene Derivatives. Photo-
chemical generation of singlet oxygen was performed using a 
magnetically stirred 60 mL cylindrical quartz reactor sur-
rounded by six 4 W black light blue (BLB) lamps (emission 
wavelength region: 350-400 nm, Philips TL4W) at ambient 
temperature (22° C.). The incident light intensity was 3.79x 
10-4 Einstein·min- 1 L- 1 . Reaction solutions containing 50 
µM of hexakis-substituted C60 fullerene derivatives 1-4 and 
0.5 mM furfuryl alcohol (FFA) as an indicator/reactant for 
singlet oxygen formed were buffered at pH=7 using 10 mM 
phosphate buffer. Thereafter, the solutions were exposed to 
the light source. As the photochemical reaction proceeded, 1 
60 used as the monitoring source. For the laser flash photolysis 
measurements, the hexakis-substituted C60 fullerene deriva-
tives were buffered at pH=7 in 10 mM phosphate buffer, and 
the concentration was adjusted to produce an absorbance of 
-0.5 absorbance units at 308 nm. The test solutions were 
65 purged with bubbling argon gas for 15 minutes and then 
sealed from the atmosphere. Instantaneous generation of the 
triplet state was induced by laser pulse irradiation with sub-
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sequent monitoring between 650 and 770 nm, depending on 
the specific functional groups present in each hexakis-substi-
tuted c60 fullerene derivative. 
FIG. 5 shows illustrative plots of triplet state decay kinetics 
in various hexakis-substituted c60 fullerene derivatives in 
comparison to fullerol. As shown in FIG. 5, all of the hexakis-
substituted c60 fullerene derivatives displayed superior trip-
let-state decay kinetics compared to commercially-available 
fullerol. The triplet state lifetimes for hexakis-substituted c60 
fullerene derivatives 1-4 ranged from 30 to 44 µs, whereas the 
triplet state lifetime for the fullerol was only -9 µs. Under 
comparable experimental conditions, triplet state formation 
was not detected in a hexane solution of pristine C60 due to 
photoquenching resulting from contact between neighboring 
C60 cages. 
Example 4 
Particle Size Measurements in Hexakis-Substituted C60 
Fullerene Derivatives. Water or phosphate buffer solutions of 
the hexakis-substituted c60 fullerene derivatives were dried 
on a carbon grid and analyzed by dynamic light scattering 
using a Zetasizer Nano ZS90 particle size analyzer having a 
detection size limit of -1 nm. FIGS. 6A and 6B show illus-
20 
tryptic soy broth media for 18 hat 37° C. The E. coil stock 
solution was prepared by resuspending the centrifuged har-
vest in 10 mM phosphate buffer after washing twice. The final 
concentration was determined by a spread plate method on 
nutrient agar after 24 h culture at 37° C. The MS-2 bacte-
riophage was obtained by inoculating E. coli C3000 grown in 
the exponential to early stationary phase with MS-2 bacte-
riophage, and quantified by a soft agar overlay (double-agar 
layer) plaque assay method. MS-2 bacteriophage stock was 
10 prepared from overlay agar plates of confluent lysis. Photo-
sensitizedmicrobial inactivation was performed using a BLB 
lamp with a light intensity low enough to ensure that UV 
irradiation alone did not induce any E. coli or MS-2 bacte-
riophage inactivation (8.4xl0-6 Einstein min- 1L-1 for E. 
15 coli; 6.lxl0-6 Einstein min- 1 L-1 for MS-2 bacteriophage). 
The reaction solutions (10 mM phosphate buffer at pH 7.0) 
for E. coli and MS-2 bacteriophage inactivation experiments 
consisted of 50 µM hexakis-substituted C60 fullerene deriva-
tive and either E.coli at 3xl05 colony forming units (CFU)/ 
20 mL or MS-2 bacteriophage at 3xl05 plaque forming units 
(PFU)/mL, respectively. During each experiment, a 1 mL 
sample was withdrawn at fixed time intervals for quantifica-
tion of E. coli and MS-2 bacteriophage. Three replicates 
analyses were performed (standard deviation <10%). 
FIG. 7 shows illustrative plots of E. coli inactivation as a 
function of irradiation time by various hexakis-substituted 
C60 fullerene derivatives in comparison to fullerol and Ti02 in 
the presence of BLB light. For each of hexakis-substituted 
c60 fullerene derivatives 1, 2 and 4, significant E. coli inacti-
trative particle size histograms for various hexakis-substi- 25 
tuted c60 fullerene derivatives deposited from a water solu-
tion and a 10 mM phosphate buffer solution. FIG. 6A shows 
the particle size histogram for hexakis-substituted c60 
fullerene derivative 2. FIG. 6B shows the particle size histo-
gram for hexakis-substituted C60 fullerene derivative 4. As 
shown in FIGS. 6A and 6B, dramatically different particle 
size distributions were observed for the hexakis-substituted 
c60 fullerene derivatives depending on the aqueous solution 
chemistry. It is notable that in spite of the fairly large particle 
agglomerates formed in aqueous solutions, production of sin-
glet oxygen still remained facile in the hexakis-substituted 
C60 fullerene derivatives. This behavior is in marked contrast 
30 vation was observed after a lag period that is commonly seen 
in bacterial disinfection kinetics. Under the tested conditions, 
no E. coli was inactivated by the fullerol or the UV light alone. 
Inactivation by hexakis-substituted C60 fullerene derivative 4 
was comparable to that produced by Ti02 , which is a com-
35 manly used material for photochemically induced bacterial 
inactivation. FIG. 8 shows illustrative plots of E. coil inacti-
vation as a function of irradiation time by hexakis-substituted 
C60 fullerene derivative 4 in UV light both in the presence and 
absence ofL-histidine scavenger and in the dark. As shown in 
to C60 , where particle aggregation causes a dramatic drop in 
its ability to photochemically generate singlet oxygen. 
Example 5 
Bacterial and Viral Inactivation ofHexakis-Substituted C60 
Fullerene Derivatives. Intrinsic antibacterial properties of 
several hexakis-substituted C60 fullerene derivatives and ful-
lerol were evaluated in the dark using a minimum inhibitory 
concentration (MIC) assay with Escherichia coli Kl 2. E. coil 
was cultured in Luria-Bertani broth and incubated at 37° C. 
overnight prior to transferring to Minimal Davis (MD) media 
(i.e., Davis media with potassium phosphate reduced by 
90% ). The cultures were diluted to a final optical density of 
0.002 at 600 nm (OD600). The hexakis-substituted C60 
fullerene derivatives were then added to the MD media at 
various concentrations. Overnight growth at 37° C. was 
assessed spectrophotometrically by measuring OD600. The 
minimal concentration of functionalized C60 fullerene deriva-
tives resulting in no turbidity (indicating no growth of E. coli) 
was denoted as the MIC. Hexakis-substituted C60 fullerene 
derivatives 1 and 3 did not inhibit E. coli growth in the dark 
(MIC>400 mM). Hexakis-substituted C60 fullerene deriva-
tive 4 displayed a mild intrinsic antibacterial activity of 120 
µM against E. coli. However, compared to pristine C60 , the 
intrinsic antimicrobial activity was relatively mild, as C60 
displayed MIC values ranging from 0.7 to 2.8 µM. 
Photoinduced bactericidal and virucidal activities of the 
hexakis-substituted C60 fullerene derivatives were assessed 
using E. coli and MS-2 bacteriophage. E. coil was cultured in 
40 FIG. 8, no bacterial inactivation was observed either in the 
dark or in the presence of the scavenger. 
FIG. 9 shows illustrative plots ofMS-2 bacteriophage inac-
tivation as a function of irradiation time by various hexakis-
substituted c60 fullerene derivatives in comparison to fullerol 
45 in the presence ofBLB light. For each ofhexakis-substituted 
C60 fullerene derivatives 1, 2 and 4, significant MS-2 bacte-
riophage inactivation was observed, particularly for hexakis-
substituted C60 fullerene derivative 4. Under the tested con-
ditions, fullerol produced very little MS-2 bacteriophage 
50 inactivation. The inactivation of the MS-2 bacteriophage 
virus is particularly significant, since viral inactivation is 
typically much more difficult to conduct under UV irradiation 
than is bacterial inactivation. 
FIG. 10 shows illustrative plots of MS-2 bacteriophage 
55 inactivation as a function of irradiation time by various con-
centrations ofhexakis-substituted c60 fullerene derivative 4. 
FIG. 11 shows illustrative plots ofMS-2 bacteriophage inac-
tivation as a function of irradiation time by hexakis-substi-
tuted C60 fullerene derivative 4 at 10 µMin UV light both in 
60 the presence and absence ofL-histidine scavenger and in the 
dark. At low concentrations of hexakis-substituted C60 
fullerene derivative 4 (-10 µM) there was no inactivation of 
MS-2 bacteriophage in the dark or in the presence of an 
L-histidine scavenger. However, unlike the behavior 
65 observed in the inactivation of E. coil, at higher concentra-
tions (-50 µM), some MS-2 bacteriophage inactivation 
occurred even in the dark or in the presence of L-histidine. 
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FIG. 12 shows illustrative plots of MS-2 bacteriophage 
inactivation as a function of irradiation time by hexakis-
substituted C60 fullerene derivative 4 in comparison to Ti02 . 
As shown in FIG. 12, hexakis-substituted C60 fullerene 
derivative 4 significantly outperformed Ti02 in its viral inac-
tivation capabilities. Under identical conditions, a concentra-
tion of 0.15 g/L of hexakis-substituted C60 fullerene deriva-
tive 4 led to a 2-log reduction ofactive MS-2 bacteriophage in 
only 4 minutes, whereas a comparable inactivation with 0.2 
g/L ofTi02 took over 3 hours to achieve. 
10 
Example 6 
Photophysical Properties and Photochemical Degradation 
15 by Silica-Bound Hexakis-Substituted C60 Fullerene Deriva-
tive 4. Hexakis-substituted C60 fullerene derivative 4 was 
covalently bound via amide bond(s) to 3-(2-succinic anhy-
dride )propyl functionalized silica gel (-0.2-0.3 mm diam-
eter), which is commercially available. Other types offunc- 20 
tionalized silica gels may be used equivalently or in a very 
similar manner. FIG. 13 shows illustrative UV-VIS reflec-
tance spectra of various concentrations ofhexakis-substituted 
c60 fullerene derivative 4 covalently bound to a functional-
ized silica gel support. The UV-VIS spectra of the surface- 25 
bound hexakis-substituted c60 fullerene derivative 4 was 
comparable to that of the unbound derivative. 
FIG. 14 shows illustrative plots of fractional FFA remain-
ing as a function ofirradiation time for various concentrations 
of silica-bound hexakis-substituted c60 fullerene derivative 4 30 
in the presence and absence of a UV cutoff filter. As shown by 
the comparable rates of FFA oxidation in the presence and 
absence of UV light, surface-bound hexakis-substituted C60 
fullerene derivative 4 was operable for singlet oxygen gen-
eration the presence of visible light. This behavior contrasts 35 
that observed for Ti02 where very little FFA oxidation is 
observed in the absence of UV light, as shown in FIG. 15. 
FIG. 15 shows illustrative plots of fractional FFA remaining 
as a function of irradiation time for Ti02 in the presence and 
absence of a UV cutoff filter. For hexakis-substituted C60 40 
fullerene derivative 4, singlet oxygen generation was facile at 
a relatively low intensity of 55 µw/cm2 . 
In addition to microbial and viral inactivation, the surface-
bound hexakis-substituted c60 fullerene derivative was active 
for removing chemical pollutants from a water source. Ran- 45 
itidine, cimetidine, propanolol and sulfisoxazole are small 
molecule pharmaceutical compounds that are emerging as 
chemical pollutants in wastewater treatment protocols. FIG. 
16 shows illustrative plots of fractional concentration as a 
function of irradiation time for ranitidine, cimetidine, pro- 50 
panolol and sulfisoxazole in the presence of silica-bound 
hexakis-substituted c60 fullerene derivative 4 at a light inten-
sity of 55 µw/cm2 (350-650 nm). As shown in FIG. 16, the 
degradation of ranitidine, cimetidine and propanolol was 
essentially complete within one hour. Although, the degrada- 55 
tion of sulfisoxazole was considerably slower, there was 
noticeable progression within two hours of irradiation. 
From the foregoing description, one of ordinary skill in the 
art can easily ascertain the essential characteristics of this 
disclosure, and without departing from the spirit and scope 60 
thereof, can make various changes and modifications to adapt 
the disclosure to various usages and conditions. The embodi-
ments described hereinabove are meant to be illustrative only 
and should not be taken as limiting of the scope of the disclo-
sure, which is defined in the following claims. 65 
What is claimed is the following: 
22 
1. An aminofullerene derivative operable forphotocatalyti-
cally generating singlet oxygen in the presence of a visible 
light source, wherein the aminofullerene derivative com-
prises: 
a fullerene cage; and 
a plurality of amine-terminated moieties covalently 
bonded to the fullerene cage, 
wherein the plurality of amine-terminated moieties 
comprise primary amines, and 
wherein the aminofullerene derivative is covalently 
bonded to a carboxylate-functionalized substrate sur-
face by amide bonds between the primary amines of 
the fullerene cage and the carboxylate group bonded 
to the substrate surface. 
2. The aminofullerene derivative of claim 1, wherein the 
fullerene cage comprises C60 . 
3. The aminofullerene derivative of claim 2, wherein the 
aminofullerene derivative comprises a hexakis-substituted 
c60 derivative. 
4. The aminofullerene derivative of claim 3, wherein the 
hexakis-substituted c60 derivative is 
0 
0 
or a salt thereof. 
5. The aminofullerene derivative of claim 2, 
wherein the aminofullerene derivative comprises C60 and a 
plurality of amine-terminated moieties covalently 
bonded to the c60, wherein the plurality of amine-termi-
nated moieties comprise primary amines. 
6. The aminofullerene derivative of claim 1, wherein the 
aminofullerene derivative comprises an aminofullerene hav-
ing a structure of 
wherein A is a C2 m fullerene cage; 
wherein m is an integer greater than or equal to 30; 
wherein X 1 and X2 are independently selected from the 
group consisting ofO and NR3 ; 
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wherein R3 is selected from the group consisting of H, 
alkyl, cycloalkyl, aryl, heteroaryl and aralkyl; 
wherein R1 and R2 contain at least one terminal amino 
group and are independently selected from the group 
consisting of alkyl, alkenyl, alkynyl, cycloalkyl, hetero-
cyclyl, aryl, heteroaryl and aralkyl groups; and 
wherein n is an integer ranging from 1 to an upper limit 
equal to half the number of hexagons in the C2 m 
fullerene cage. 
7. The aminofullerene derivative of claim 6, wherein A is 10 
C60 and n is an integer ranging from 1 to 6. 
8. The aminofullerene derivative of claim 1, wherein the 
primary amines comprise cationic amines. 
9. The aminofullerene derivative of claim 1, wherein the 
carboxylate-functionalized substrate surface comprises 15 
silica. 
* * * * * 
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